Synapse - Gopakumar Iyer

Results (25)

Targeting nucleotide excision repair defects in cancer

Meeting Abstract

Topka, S.; Steinsnyder, Z.; Tkachuk, K.; Ravichandran, V.; Madsen, M. W.; Furberg-Barnes, H.; Iyer, G.; De Stanchina, E.; Joseph, V.; Offit, K.
Molecular Cancer Therapeutics (2019)

Fulltext@MSK | Save

"Primary" and "secondary" muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes

Correspondence

Pietzak, E. J.; Al-Ahmadie, H.; Walasek, A.; Bajorin, D. F.; Rosenberg, J. E.; Bochner, B. H.; Solit, D. B.; Iyer, G.
Translational Cancer Research (2019)

Fulltext@MSK | Save

Activity of M3814, an oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models

Journal Article

Wise, H. C.; Iyer, G. V.; Moore, K.; Temkin, S. M.; Gordon, S.; Aghajanian, C.; Grisham, R. N.
Scientific Reports (2019)

Fulltext@MSK | Save

Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations

Meeting Abstract

Varghese, A. M.; Patel, J. A. A.; Janjigian, Y. Y.; Meng, F.; Selcuklu, S. D.; Zimel, C.; Hyman, D. M.; Iyer, G.; Houck-Loomis, B.; Abou-Alfa, G. K.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)

Meeting Abstract

Mota, J. M.; Teo, M. Y.; Whiting, K.; Ostrovnaya, I.; Li, H.; Lee, C. H.; Funt, S. A.; Callahan, M. K.; Iyer, G.; Bajorin, D. F.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)

Meeting Abstract

Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?

Meeting Abstract

Mota, J. M. S. C.; Teo, M. Y.; Li, H.; Balar, A. V.; Milowsky, M. I.; Funt, S. A.; Lee, C. H.; Regazzi, A. M.; Berger, M. F.; Solit, D. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)

Meeting Abstract

Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Muscle invasive bladder cancer (MIBC) demonstrates neoadjuvant cisplatin-based chemotherapy (NAC) related changes in molecular subtype and immune infiltration